| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
The Ensign Group, Inc.
$179.85
-2.64 (-1.45%)
Market Cap
10.48 B
EPS
6.50
P/E Ratio
27.68 $
Value Trade
60.23 M
-0.99 %
Week
6.35 %
1 Month
4.6 %
3 Month
-14.62 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
303.59 K
52 Week Range
141.58 - 218
% held by Insiders
3.6 %
% held by Institutions
91.42 %
Enterprise Value
10.30 B
Total Shares
58.28 M
Short %
2.99 %
Float Shares
56.07 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
ENSG Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENSG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENSG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ENSG
Aug 20, 2026▼ -1.4%today
The Ensign Group Increases Credit Facility to $800 Million and Extends Maturity
The Ensign Group has amended its revolving credit facility, increasing it to $800 million and extending the maturity date to August 19, 2031. This move aims to enhance liquidity and support the company's growth strategy, including acquisitions and capital investments. The CEO expressed confidence in the company's financial strength and disciplined growth approach.
Read more →-ENSG
Jul 27, 2026The Ensign Group Reports Second Quarter 2026 Results
The Ensign Group reported strong second quarter results for 2026, with GAAP diluted earnings per share of $1.68 and adjusted earnings per share of $1.92. The company raised its annual earnings and revenue guidance, reflecting confidence in its growth strategy and operational performance. Clinical outcomes were notably superior, with high-quality care ratings and improved occupancy rates across its facilities.
Read more →-ENSG
Jul 2, 2026The Ensign Group Purchases Real Estate and Operations in Texas
The Ensign Group has acquired two skilled nursing facilities in Texas, enhancing its operations in the state. The facilities, Las Ventanas de Socorro and Los Arcos del Norte Care Center, add to Ensign's growing portfolio, which now includes 398 healthcare operations across 17 states. The acquisition is part of Ensign's strategy to expand its real estate and healthcare services.
Read more →-ENSG
Jun 15, 2026The Ensign Group, Inc. Announces Increased Stock Repurchase Authorization
The Ensign Group, Inc. has announced a $60 million increase to its stock repurchase program, raising the total authorization to $100 million. This decision reflects the company's strong financial performance and commitment to disciplined capital allocation. The repurchase program will commence soon, but actual repurchases will depend on various market factors.
Read more →-ENSG
Jun 2, 2026The Ensign Group Acquires Real Estate and Operations in Iowa
The Ensign Group has acquired Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa, effective June 1, 2026. This acquisition is part of Ensign's strategy to expand its operations in the Midwest, with the company expressing optimism about growth in Iowa. Additionally, Ensign also acquired a memory care facility in California on the same day.
Read more →-ENSG
Jun 2, 2026The Ensign Group Purchases Memory Care Facility in California
The Ensign Group, Inc. has acquired 'Memory Care of Contra Costa', a 46-unit memory care facility in Pleasant Hill, California, through its subsidiary Standard Bearer Healthcare REIT, Inc. This acquisition, effective June 1, 2026, is part of Ensign's strategy to expand its healthcare portfolio, which now includes 396 operations across 17 states. Additionally, Ensign has also acquired 'Woodland Health and Rehabilitation', a skilled nursing facility in Iowa.
Read more →-ENSG
Apr 28, 2026The Ensign Group Schedules First Quarter 2026 Earnings Call for Friday, May 1, 2026
The Ensign Group, Inc. has announced its first quarter 2026 earnings call scheduled for May 1, 2026. The company will release its financial results on April 30, 2026, and invite investors to participate in a live webcast. This event will provide insights into the company's performance and future outlook.
Read more →-ENSG
Mar 20, 2026The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share
The Ensign Group, Inc. has announced a quarterly cash dividend of $0.0650 per share, payable on or before April 30, 2026. Shareholders of record as of March 31, 2026, will be eligible for this dividend. The company has consistently paid dividends since 2002, indicating strong financial stability.
Read more →-ENSG
Feb 3, 2026The Ensign Group Adds Real Estate and Operations in Texas
The Ensign Group has acquired the real estate and operations of Wylie Oaks Healthcare and Rehabilitation, a skilled nursing facility in Wylie, Texas, effective February 1, 2026. This acquisition, part of a series of transactions, aims to expand Ensign's presence in Texas and enhance its portfolio of healthcare operations. Ensign's CEO expressed optimism about the facility's location and the potential for quality care in the community.
Read more →-ENSG
Feb 3, 2026The Ensign Group Buys Real Estate and Operations in Wisconsin
The Ensign Group has acquired Timber Ridge Health and Rehabilitation, a 48-bed skilled nursing facility in Stevens Point, Wisconsin, effective February 1, 2026. This acquisition, part of a series of transactions, enhances Ensign's presence in the Wisconsin market and increases its total healthcare operations to 378 across 17 states. The facility will be operated by an Ensign-affiliated tenant.
Read more →-ENSG
Feb 3, 2026The Ensign Group Grows Operations in Arizona
The Ensign Group, Inc. has announced the acquisition of Agave Grove Post Acute, a 225-bed skilled nursing facility in Glendale, Arizona, effective February 1, 2026. This acquisition is part of Ensign's ongoing expansion strategy in Arizona, aiming to enhance its portfolio of healthcare operations. The company now operates 378 healthcare facilities across 17 states, with plans for further acquisitions.
Read more →-ENSG
Oct 1, 2019Ensign Group Completes Spin-off of Pennant Group
Ensign Group Completes Spin-off of Pennant Group SAN JUAN CAPISTRANO, Calif., October 1, 2019 - The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of the Ensign group of skilled nursing, rehabilitative care services, home health care, hospice care, senior living and other
Read more →Competitive Position
How ENSG ranks across every disease it competes inCompetitive Position is a premium feature
See how ENSG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial